What is Wedbush's Estimate for APLS FY2029 Earnings?

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) - Equities research analysts at Wedbush lifted their FY2029 earnings per share estimates for Apellis Pharmaceuticals in a research report issued on Monday, March 3rd. Wedbush analyst L. Chico now expects that the company will post earnings per share of $3.79 for the year, up from their prior estimate of $3.77. Wedbush currently has a "Neutral" rating and a $29.00 price target on the stock. The consensus estimate for Apellis Pharmaceuticals' current full-year earnings is ($1.70) per share.

A number of other equities research analysts have also recently commented on APLS. The Goldman Sachs Group lowered their price target on shares of Apellis Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating on the stock in a report on Monday. Robert W. Baird cut their price target on Apellis Pharmaceuticals from $92.00 to $55.00 and set an "outperform" rating for the company in a research note on Thursday, November 7th. JPMorgan Chase & Co. boosted their price objective on Apellis Pharmaceuticals from $50.00 to $54.00 and gave the company an "overweight" rating in a research note on Tuesday. Royal Bank of Canada cut their target price on shares of Apellis Pharmaceuticals from $26.00 to $25.00 and set a "sector perform" rating for the company in a research report on Monday. Finally, Morgan Stanley started coverage on shares of Apellis Pharmaceuticals in a research report on Thursday, November 21st. They issued an "equal weight" rating and a $31.00 price target on the stock. Eight research analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Apellis Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus target price of $45.53.

Remove Ads

Apellis Pharmaceuticals Stock Performance

APLS stock traded down $0.28 during mid-day trading on Tuesday, hitting $25.04. The company had a trading volume of 1,520,174 shares, compared to its average volume of 1,920,320. The company has a debt-to-equity ratio of 1.91, a quick ratio of 3.73 and a current ratio of 4.36. The firm has a market cap of $3.11 billion, a PE ratio of -12.33 and a beta of 0.93. Apellis Pharmaceuticals has a 12 month low of $23.77 and a 12 month high of $63.40. The stock's fifty day moving average price is $29.23 and its two-hundred day moving average price is $31.22.

Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last released its earnings results on Friday, February 28th. The company reported ($0.29) EPS for the quarter, topping analysts' consensus estimates of ($0.37) by $0.08. The company had revenue of $212.50 million for the quarter, compared to analysts' expectations of $197.92 million. Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The business's revenue for the quarter was up 45.2% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.73) EPS.

Insider Buying and Selling

In other news, insider Caroline Baumal sold 2,816 shares of the stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $33.81, for a total transaction of $95,208.96. Following the completion of the sale, the insider now directly owns 55,560 shares in the company, valued at approximately $1,878,483.60. This represents a 4.82 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, General Counsel David O. Watson sold 5,569 shares of the business's stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $25.10, for a total value of $139,781.90. Following the transaction, the general counsel now owns 138,730 shares in the company, valued at approximately $3,482,123. This represents a 3.86 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 65,934 shares of company stock worth $1,950,261. Corporate insiders own 6.80% of the company's stock.

Institutional Investors Weigh In On Apellis Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of APLS. EverSource Wealth Advisors LLC raised its holdings in shares of Apellis Pharmaceuticals by 2,707.1% during the fourth quarter. EverSource Wealth Advisors LLC now owns 786 shares of the company's stock valued at $25,000 after acquiring an additional 758 shares in the last quarter. Wolverine Asset Management LLC bought a new position in Apellis Pharmaceuticals in the 3rd quarter worth $27,000. True Wealth Design LLC purchased a new stake in shares of Apellis Pharmaceuticals in the 3rd quarter worth about $27,000. Signaturefd LLC boosted its stake in shares of Apellis Pharmaceuticals by 357.2% during the 4th quarter. Signaturefd LLC now owns 1,175 shares of the company's stock valued at $37,000 after purchasing an additional 918 shares in the last quarter. Finally, Capital Performance Advisors LLP purchased a new position in shares of Apellis Pharmaceuticals during the third quarter valued at about $56,000. Hedge funds and other institutional investors own 96.29% of the company's stock.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).